Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $190.2 million.

  • Gsk's Non Operating Income rose 122614.32% to $190.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.5 million, marking a year-over-year increase of 25355.26%. This contributed to the annual value of $699.2 million for FY2024, which is 1696.44% down from last year.
  • Latest data reveals that Gsk reported Non Operating Income of $190.2 million as of Q3 2025, which was up 122614.32% from $178.8 million recorded in Q2 2025.
  • Gsk's 5-year Non Operating Income high stood at $446.9 million for Q4 2022, and its period low was -$1.0 billion during Q4 2021.
  • Its 5-year average for Non Operating Income is $1.6 million, with a median of $136.0 million in 2025.
  • In the last 5 years, Gsk's Non Operating Income plummeted by 49696.48% in 2021 and then soared by 122614.32% in 2025.
  • Quarter analysis of 5 years shows Gsk's Non Operating Income stood at -$1.0 billion in 2021, then surged by 143.74% to $446.9 million in 2022, then fell by 9.46% to $404.6 million in 2023, then fell by 9.91% to $364.5 million in 2024, then tumbled by 47.82% to $190.2 million in 2025.
  • Its Non Operating Income stands at $190.2 million for Q3 2025, versus $178.8 million for Q2 2025 and $136.0 million for Q1 2025.